In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line

Authors: B.A. Stander, S. Marais, C.J.J. Vorster and A.M. Joubert

Department of Physiology, University of Pretoria, Pretoria, South Africa

1. Introduction

2-Methoxyestradiol (2ME) is an endogenous metabolite of 17β-estradiol exerting both antiangiogenic and antimitogenic effects in vitro and in vivo [1]. 2ME is a target for 17β-hydroxysteroid dehydrogenase-mediated metabolism that explains its low bioavailability due to rapid metabolic breakdown [2]. Results from preclinical tumor models in animals suggest that maintaining a plasma concentration of 2ME in the range of 3-17ng/ml (10-56nM) is needed for efficient anti-tumor activity [3-4]. 2ME is registered as Panzem® by Entremed, Inc. (Rockville, MD) and is currently being used in clinical trials by making use of a novel nanocrystal dispersion (NCD) drug delivery system [5]. The NCD formulation of 2ME was shown to have improved bioavailability resulting in plasma concentration levels within the range needed for anti-tumor activity [3].

2ME plays a role in the abrogation of microtubule dynamics and the inhibition of protein translation and activity of the anaphase-promoting complex (APC/C) [6]. 2ME inhibits angiogenesis by interacting with endothelial tubulin dynamics which in turn negatively affects the expression and activity of hypoxia-inducible factor 1-alpha (HIF-1α) and vascular endothelial growth factor (VEGF) [7-8]. 2ME can also induce antiangiogenic effects through apoptosis as a result of increased phosphorylation of protein kinase B (Akt), activation of c-jun N-terminal (JNK), extracellular signal-regulated (ERK) and p38-kinases, activation of the intrinsic apoptotic pathway through inactivation of B-cell lymphoma 2 (Bcl-2) and Bcl-xL proteins as well as the upregulating the extrinsic pathway by increasing the expression of death receptor 5 (DR5) leading to activation of caspase-8 [6, 8-14]. Fukui and Zhu (2008) demonstrated that 2ME induced the phosphorylation of Bcl-2 proteins, but did not significantly alter the levels of Bcl-2-associated X protein (Bax) and Bcl-2 expression in MDA-MB-435 M14 melanoma derived metastatic cells [13, 15]. This is in contrast to the results found by Joubert et al. (2005) wherein 2ME altered the ratio of Bax/Bcl-2 expression levels in esophageal
cancer cells and cervical carcinoma cells [16-17]. In addition, 2ME induces apoptosis through the p38 pathway and not the JNK pathway in ovarian carcinoma cells, but activates and induces apoptosis through both the JNK and p38 pathways in prostate cancer cells [18-19]. MCF-7 cells are known to be caspase-3 deficient, since they do not express the CASP-3 gene as a result of a 47-base pair deletion within exon 3 of the gene, thus causing abrogated translation of CASP-3 mRNA [20]. These observations, among others, indicate that the mechanism of action of 2ME-induced growth inhibition is cell line specific.

Since the exact mechanism of 2ME’s action is cell line specific and remains to be elucidated, the purpose of this study was to investigate the in vitro influence of 2ME in the MCF-7 breast adenocarcinoma cell line. The MCF-7 cell line is a tumorigenic estrogen receptor positive breast cell line that lacks caspase 3 expression [20]. Data obtained from the influence of 2ME on cyclin B1 levels, its effect on the release of cytochrome c, the generation of reactive oxygen species, as well as information obtained from its influence on global gene expression further contribute to the mechanism exerted by 2ME on tumorigenic breast cancer cells. In addition, a novel finding namely the induction of both apoptosis and autophagy as a possible combination of types of cell death induced by 2ME in MCF-7 cells is proposed.

2. Materials and Methods

2.1. Material

Heat-inactivated fetal calf serum (FCS), sterile cell culture flasks and plates were obtained through Sterilab Services (Kempton Park, Johannesburg, South Africa). Dulbecco’s minimum essential medium Eagle (D-MEM), penicillin, streptomycin and fungizone were purchased from Highveld Biological (Pty) Ltd. (Sandringham, SA). 2ME was supplied by Sigma-Aldrich (St. Louis, United States of America). An Annexin V-FITC Kit and an anti-cytochrome c FITC-conjugated antibody set were purchased from BIOCOM biotech (Pty) Ltd. (Clubview, South Africa). A fluorescein-FITC conjugated cyclin B1 antibody reagent set was purchased from The Scientific Group (Johannesburg, South Africa). Qiagen’s Plant Mini Kit, PCR Clean-up kit, RNase-free DNase and Qiazol were purchased from Southern Cross Biotechnology (Pty) Ltd. (Cape Town, South Africa). The Nanodrop, an Axon Genepix 4000B Scanner and Agilent’s SureHyb chambers at the African Centre of Gene Technology (ACGT) Microarray Facility (University of Pretoria, Pretoria, South Africa) were purchased from Inqaba Biotechnical Industries (Pty) Ltd. (Pretoria, SA), Molecular Devices Corporation, (Sunnyvale, California, United States of America) and Agilent Technologies (Pty) Ltd. (Palo Alto, California, United States of America) respectively. The fluorescence activated cell sorting (FACS) FC500 System flow cytometer equipped with an air-cooled argon laser excited at 488 nm was purchased from Beckman Coulter South Africa (Pty) Ltd. (Pretoria,
South Africa). Agilent’s 44k 60-mer human oligo slides, Low RNA Input Fluorescent Linear Amplification Kit, 2x GEx Hybridization Buffer HI-RPM, Gene Expression (GE) Wash Buffer 1 and 2 and the Stabilization and Drying Solution were purchased from Agilent Technologies (Pty) Ltd. (Palo Alto, California, United States of America). All other chemicals were of analytical grade and were purchased from Sigma Chemical Co. (St. Louis, MO, USA).

2.2. Cell culture

The MCF-7 cell line (human breast epithelial carcinoma) was supplied by Highveld Biological (Pty) Ltd. (Sandringham, Johannesburg, South Africa). Cells were grown and maintained in 25 cm² tissue culture flasks in a humidified atmosphere at 37°C, 5% CO₂ in a Forma Scientific water-jacketed incubator (Ohio, United States of America). MCF-7 cells were cultured in DMEM and supplemented with 10% heat-inactivated FCS (56°C, 30 min), 100 U/ml penicillin G, 100 µg/ml streptomycin and fungizone (250 µg/l). A stock solution of 2 mM 2ME dissolved in dimethyl sulfoxide (DMSO) was prepared and diluted with medium to the desired concentrations prior to exposure of the cells. The medium of all control cells was supplemented with an equal concentration of DMSO (vehicle). The DMSO content of the final dilutions never exceeded 0.1% (v/v). A final concentration 1 µM 2ME was employed in all our studies, since Van Zijl et al. (2008) determined this to be the optimal concentration for the inhibition of growth in MCF-7 cells through dose-dependent investigations conducted in our laboratory [11]. Experiments were performed in either 6-well plates or 25 cm² cell culture flask. For six-well plates, exponentially growing cells were seeded at 250 000 cells per well in 3 ml maintenance medium in 6-well plates on heat-sterilized coverslips. After a 24 h incubation period at 37°C to allow for cell adherence, cells were exposed to 1µM 2ME and vehicle respectively and incubated for 24 h at 37°C. For 25 cm² cell culture flasks, exponentially growing MCF-7 cells were seeded at 1x10⁶ cells per 25 cm² flask to a final volume of 5 ml of maintenance medium. After 24 h attachment the medium was discarded and the cells were exposed to 1 µM 2ME (5 ml medium) and incubated for 24 h.

2.3. Flow cytometric quantification of cyclin B1 and cell cycle progression determination

A cyclin B1-fluorescein isothiocyanate (FITC) conjugated antibody was used in order to quantify cyclin B1 protein by employing flow cytometric analyses. After 24 h treatment in 25 cm² flasks, cells were trypsinized and fixed with 10 ml ice-cold 70% ethanol and stored at 4°C for 24 h. After 24 h, the cells were trypsinized and washed with PBS. Cells (1x10⁶) were incubated with either FITC-conjugated mouse immunoglobulin G (IgG) as a control or FITC-conjugated cyclin B1 for 30 min at room temperature. Cells were washed and resuspended in 0.5 ml PBS containing 40 µg/ml propidium iodide and 100 µg/ml RNase A for 30 min at 4°C.
FITC (FL1) and propidium iodide (FL3) fluorescence were measured with a FC500 System flow cytometer (Beckman Coulter South Africa (Pty) Ltd.) equipped with an air-cooled argon laser excited at 488nm. Data from at least 10 000 cells were analyzed with CXP software (Beckman Coulter South Africa (Pty) Ltd). Aggregated and aneuploid cells were removed from analysis by visual inspection. For cyclin B1 analyses, fluorescence of the FITC-conjugated isotypic control was normalized to 2% on an FL1-log vs FL3-lin dot-plot. Measurement of FITC-conjugated cyclin B1 fluorescence of control and exposed MCF-7 cells were measured utilizing the normalized area of the dot-plot. For cell cycle analyses, results are expressed as percentage of the cells in each phase. Cell cycle distributions from histograms generated by the CXP software were calculated with Multicycle (Phoenix Flow Systems, San Diego, CA).

2.4. Flow cytometric measurement of hydrogen peroxide and superoxide

Hydrogen peroxide (H$_2$O$_2$) generation was assessed using 2,7-dichlorofluorescein diacetate (DCFDA), a non-fluorescent probe, which upon oxidation by ROS and peroxides is converted to the highly fluorescent derivative DCF [21]. Superoxide generation was assessed using hydroethidine (HE). HE is oxidized by superoxide and not by hydroxyl radicals, singlet O$_2$, H$_2$O$_2$ or nitrogen radicals to a red fluorescing compound [22]. After 24 h exposure, cells were trypsinized, washed with PBS and 1x10$^6$ cells were resuspended in 1 ml PBS. Cells were incubated with 20 µM DCFDA for 25 min and 10 µM HE for 15 min at 37°C. Hydrogen peroxide (20 µM) was added 5 min prior to measurement as a positive control for DCF formation. For DAF2-DA, 5 µM was added to the cells in PBS and incubated for 45 min at 37°C. DCF (FL1) and HE fluorescent product fluorescence (FL2) were measured with a FACS FC500 System flow cytometer equipped with an air-cooled argon laser excited at 488nm.

2.5. Morphology study – Fluorescent microscopy

A double fluorescent dye staining method was utilized in order to determine the effect that 2ME has on acidic vesicular organelle formation. Acridine orange is a lysosomotropic fluorescent compound that serves as a tracer for acidic vesicular organelles including autophagic vacuoles and lysosomes [23]. Cells undergoing autophagy will have an increased tendency for acridine orange staining when compared to viable cells. Hoechst 33342 is a fluorescent dye that can penetrate intact cell membranes of viable cells and cells undergoing apoptosis and stains the nucleus. After 24 h treatment in six well plates, 0.5 ml of Hoechst 33342 solution (3.5 µg/ml in PBS) was added to the medium to provide a final concentration of 0.9 µM and incubated for 30 min at 37°C in a CO$_2$ incubator. After 25 min, 0.5 ml of acridine orange solution (4 µg/ml) was added to the medium to provide a final concentration of 1
µg/ml and incubated for 5 min at 37°C. Within 5 min the cover slips were mounted on microscope slides with mounting fluid (90% glycerol, 4% N-propyl-gallate, 6% PBS). The cells were examined with a Zeiss inverted Axiovert CFL40 microscope and Zeiss Axiovert MRm monochrome camera using Zeiss Filter 2 for Hoechst 33342 (blue emission) stained cells and Zeiss Filter 9 for acridine orange-stained (green emission) cells. In order to prevent fluorescent dye quenching, all procedures were performed in a dark room.

2.6. Morphology study – Transmission electron microscopy

Transmission electron microscopy (TEM) was used to determine the ultrastructure of intracellular components of exposed- and control cells. After 24 h treatment in 25 cm² flasks, cells were trypsinized, fixed in 2.5% glutaraldehyde in 0.075 M phosphate buffer (pH 7.4-7.6) and washed with 0.075 M phosphate buffer. Thereafter the cells were fixed in 0.25% aqueous osmium, dehydrated with increasing concentrations of ethanol (30%, 50%, 70%, 90%, 100%, 100%, 100%) and embedded in Quetol resin. Ultra-thin sections were prepared with a microtome and mounted on a copper grid. Samples were contrasted with 4% uranyl acetate and Reynolds’ lead citrate. Samples were viewed with a Multi-purpose Philips 301 TEM at the Electron Microscopy unit of the University of Pretoria (Pretoria, South Africa).

2.7. Flow cytometric detection of Annexin V surface staining and propidium iodide permeability

Flow cytometric analyses were employed to measure indications of apoptosis. Annexin V was employed to measure the translocation of the membrane phospholipids, phosphatidylserine (PS), which is associated with apoptotic processes. Annexin V is a 35-36 kDa, Ca²⁺-dependent, phospholipid binding protein with a high affinity for PS. After treatment in 25 cm² flasks, cells were trypsinized and 1x10⁶ cells were double-stained with Annexin V-FITC and propidium iodide according to the manufacturer’s instructions (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Propidium iodide (FL3) fluorescence and Annexin V (FL1) fluorescence were measured with a FACS FC500 System flow cytometer (Beckman Coulter South Africa (Pty) Ltd) equipped with an air-cooled argon laser excited at 488nm. Data from at least 30 000 cells were analyzed with CXP software (Beckman Coulter South Africa (Pty) Ltd).
2.8. Flow cytometric quantification of cytochrome c

An anti-cytochrome c FITC-conjugated antibody was employed to measure the mitochondrial-released intracellular cytochrome c levels. After 24 h of treatment in 25 cm² flasks, cells were trypsinized and 1x10⁶ cells were resuspended in 1 ml PBS. Cells were stained with FITC-conjugated mouse immunoglobulin G (IgG₁) as a control or FITC-conjugated cytochrome c. Staining was conducted according to the manufacturer’s instructions (Assay Designs Inc, Michigan, USA). FITC (FL1) fluorescence was measured with a fluorescence activated cell sorting (FACS) FC500 System flow cytometer (Beckman Coulter South Africa (Pty) Ltd.) equipped with an air-cooled argon laser excited at 488 nm. Data from at least 10 000 cells were analyzed with CXP software (Beckman Coulter South Africa (Pty) Ltd). Fluorescence of the FITC-conjugated isotypic control was normalized to 1% for FL1-Log histograms and FITC-conjugated cytochrome c fluorescence of control- and exposed MCF-7 cells were plotted utilizing the normalized area of the histogram plot generated by the CXP software.

2.9. Microarray analysis of gene expression

Agilent’s Human 1A Oligo 60-mer Microarray (V2) 44k slides were used to study expression changes induced by 24 h treatment of 2ME. A dye-swop methodology was employed whereby total RNA from vehicle-control and exposed cells from two biological replicates were combined per slide.

2.10. RNA extraction and integrity

Total RNA was isolated from vehicle-control and exposed MCF-7 cells using Qiagen’s RNeasy with subsequent Qiazol purification. Cells were lysed with beta-mercaptoethanol containing guanidine isothiocyanate and the lysate was applied to QIAshredder spin columns and centrifuged for 2 min at 9000 x g. 1 ml Qiazol reagent was added to the flow-through and left for 5 min after which 0.3 ml chloroform was added. The sample was shaken vigorously and left at room temperature for 10 min. After 10 min the sample was centrifuged for 15 min at 4°C at 12000 x g. The upper aqueous phase was removed and 1 volume 70% ethanol was added and gently mixed. This solution was divided into Qiagen Plant Mini Kit columns (700µl per column) and centrifuged for 15 s at 9000 x g. The flow-through was discarded and an on-column RNase-free DNase DNA digestion procedure to remove and DNA contaminants was followed as per the manufacturer’s instructions. After washing the total RNA was quantified with a Nanodrop and tested for integrity by electrophoresis with a 1.5% agarose-formaldehyde gel. RNA was considered pure of organic
contamination (e.g. ethanol or phenol) with a 260/230 ratio greater than 1.5 and pure of protein contamination with a 260/280 ratio greater than 2. Only pure total RNA was used for cRNA synthesis. RNA was considered completely intact when clear 28S and 18S rRNA bands, with a 28S:18S intensity ratio was approximately 2:1.

2.11. **Probe preparation, hybridization and microarray slide washing**

Agilent’s Low RNA Input Fluorescent Linear Amplification Kit was used to generate fluorescently labeled cRNA. Briefly, 5 µg total RNA from exposed and control-exposed RNA samples were used for amplification into double stranded DNA utilizing an MMLV-Reverse transcriptase and dT-T7 primer. Labeled cRNA was produced using the T7 polymerase and washed using Qiagen’s RNeasy Mini kits. 825 ng cRNA was fragmented for 30 min at 60°C and subsequently hybridized to Agilent Human 1A (V2) oligonucleotide 44K microarray slides according to the manufactures guidelines using Agilent’s 2x GEx Hybridization Buffer HI-RPM in Agilent’s SureHyb chambers. Hybridization was carried out over 17 h in the dark in a rotating hybridization chamber set at 65°C and 10 rpm. Slides were washed using Agilent’s Gene Expression Wash Buffer and Stabilization and Drying Solution according to recommendations. The slides were disassembled in Agilent’s Gene Expression (GE) Wash Buffer 1 and washed for 1 min at room temperature. The slides were transferred to GE Wash Buffer 2 at elevated temperature (37°C) and washed for 1 min and then transferred to pure acetonitrile for 10 s. The slides were then transferred to Stabilization and Drying Solution for 30 s after which it was scanned immediately after careful removal from the solution.

2.12. **Scanning and data analysis - Microarray**

Slides were scanned with the Axon Genepix 4000B Scanner (Molecular Devices Corporation, Sunnyvale, CA, USA) provided by the African Centre of Gene Technology (ACGT) Microarray Facility at the University of Pretoria, Pretoria, South Africa. Spotfinding was performed using Genepix Pro 6.1 (Molecular Devices Corporation, Sunnyvale, CA, USA). Saturated spots, spots with an uneven background, non-uniform spots and spots with a low intensity vs. background ratio were removed from further analysis by excluding the spots that satisfied the following parameters. The following features were flagged as “Bad” and were removed from further analysis using Genepix 6.1 software:

Saturated spots: 
\[ F532 \% \text{ Sat.}> 30 \text{ And } [\text{Ratio of Means (635/532)}] > 0.75 \text{ Or } [F635\ \% \text{ Sat.}] > 30 \text{ And } [\text{Ratio of Means (635/532)}] < 1.3333 \]
Spots with an uneven background: ([B635 Mean] > (1.5*[B635 Median]) Or [B532 Mean] > (1.5*[B532 Median])) And ([B635 Median] > 40 Or [B532 Median] > 40)

Non-uniform spots: [Ratio of Medians (635/532)] > (4.0*[Rgn Ratio (635/532)]) Or [Ratio of Medians (635/532)] < (0.25*[Rgn Ratio (635/532)])

Low intensity vs. background ratio: [% > B635+2SD] < 10 Or [% > B532+2SD] < 10

Statistical analysis after spotfinding was conducted using Limma with the LimmaGUI interface [24-25]. Background correction was done with the normal+exponential (Normexp) convolution model with an offset value set to 50 [26-27]. Genepix Flag weightings that were flagged as “Bad” were excluded from further analysis. Normalization within arrays was performed with the Global Loess method and Aquantile normalization between arrays was performed in order to normalize expression intensities so that the intensities and log-ratios have similar distributions across a series of arrays [27]. The Least squares linear model fit method was employed and the P-values were adjusted for multiple testing utilizing the Benjamini and Hochberg’s step-up method for controlling the false discovery rate [28]. Genes that had a B-value of greater than zero were considered statistically significantly differentially expressed. The B-statistic is defined as log-odds that that gene is differentially expressed and a B-statistic of zero corresponds to a 50/50 chance that the gene is differentially expressed [27]. The gene names acquired from the gene expression list of genes considered differentially expressed were converted to Entrez Gene IDs utilizing the DAVID Gene ID Conversion Tool [29]. Biologic interpretation and functional analysis of the converted gene lists were performed by mapping differentially expressed genes to biochemical pathways and Gene Ontology (GO) categories using Gene Annotation Co-occurrence Discovery (GENECODIS) [30]. Graphical biochemical pathways were designed with CellDesigner 3.5.1 [31].

2.13. Statistical analysis of data

Data obtained from three independent experiments (each conducted in six replicates) are shown as the mean ±SD and were statistically analyzed for significance using the analysis of variance (ANOVA)-single factor model followed by a two-tailed Student’s t-test. Means are presented in bar charts, with T-bars referring to standard deviations. P-values < 0.05 were regarded as statistically significant and indicated by an asterisk (*). Measurement of FITC-and DCF-derived fluorescence was expressed as a percentage of the value measured for vehicle-treated exposed cells (relative fluorescence).
3. Results

3.1. Flow cytometric quantification of cyclin B1 and cell cycle progression determination

Intracellular cyclin B1 levels were evaluated by means of flow cytometric analyses. Cyclin B1 levels were increased in 2ME-treated cells during the G$_2$/M phase when compared to the vehicle-treated control (Figures 1 and 2). An increase to 38±7% was observed in 2ME-treated cells when compared to vehicle-treated control cells (16±3.7%) (Figure 2). DNA content analyses by means of flow cytometry showed a statistically significant increase in the G$_2$/M phase in 2ME-treated cells (23.07±1.7%) compared to vehicle-treated cells (19.3±0.9%) (Figures 3 and 4). Vehicle-treated cells also showed a marked increase in S-phase (61.7±4.1%) when compared to 2ME-treated cells (32.6±5.5%), while 2ME-treated showed a marked increase in the sub-G$_1$ population (14.8±1.2%) when compared to the vehicle-treated cells (0.98±0.3%) (Figures 3 and 4). These results suggest that 2ME-treated cells in the G$_2$/M phase enter stages of apoptosis (sub-G$_1$); rather than completing mitosis, entering G$_1$-phase and subsequently entering the S-phase.

3.2. Flow cytometric measurement of hydrogen peroxide and superoxide

In order to investigate the extent of hydrogen peroxide and superoxide production in 2ME-treated cells compared to vehicle-treated, flow cytometric analyses of MCF-7 cells loaded with the H$_2$O$_2$-sensitive the fluorophore DCFDA and the superoxide sensitive probe HE were conducted. Figure 5A shows an increase in mean fluorescence intensity of DCF in 2ME-treated cells when compared to vehicle-treated cells. Statistical analyses indicate a 1.54±0.17-fold increase over the vehicle-treated control, while the 20 µM H$_2$O$_2$-treated positive control indicated a 1.92±0.33-fold increase in mean fluorescence intensity when compared to the vehicle-treated control (Figure 5B). These results indicate that 2ME induces H$_2$O$_2$ formation in MCF-7 cells. No significant differences in superoxide levels between 2ME-treated and vehicle-treated control cells were observed (P = 0.36) (Figures 6A and 6B).

3.3. Morphology study – Fluorescent microscopy

Hoechst 33342 staining of 1 µM 2ME-treated revealed an increase in cells in metaphase, as well as an increase in the amount of cells in tripolar metaphase when compared to the vehicle-treated control (Figure 7A and 7B). Apoptotic body formation was not as prominent in 2ME-treated cells (data not shown) when compared to Actinomycin D-treated cells (Figure 7C). Acridine orange was
used as a lysosomotropic tracer for acidic vesicular organelles including autophagic vacuoles and lysosomes [23]. Cells undergoing autophagy will have an increased tendency for acridine orange staining when compared to viable cells. Qualitative analyses of 1 µM 2ME-treated showed an increase in acridine orange staining when compared to the vehicle-treated controls cells (Figure 8A and 8B). The increased staining effect was more pronounced in cells that were in metaphase block (Figure 7B and 8B). Actinomycin D-treated (0.2 µg/ml) cells in late stages of apoptosis showed a decrease in staining with acridine orange (Figure 8C).

3.4. Morphology study – Transmission electron microscopy

An increase in the formation of vacuoles in 2ME-treated cells was observed by means of transmission electron microscopy when compared to vehicle-treated cells (Figure 9A and 9B). This suggests, although not conclusively, an increase in autophagic activity as revealed above by acridine orange staining. Hypercondensed chromatin was observed in Actinomycin D-treated cells, indicating late stages of apoptosis (Figure 9C).

3.5. Flow cytometric detection of Annexin V surface staining and propidium iodide permeability

Quantitative analyses of the externalization of the membrane phosphatidylserine with Annexin V were determined in order to detect early and late apoptotic processes. Propidium iodide measured the amount of necrotic cells. 2ME-treated cells showed an increase in early and late stages of apoptosis when compared to the vehicle-treated cells. (Figures 10A-B). 2ME-treated cells revealed 11.14% cells to be present in early apoptosis and 3.95% of cells were in late stages of apoptosis (Table 1).

3.6. Flow cytometric quantification of cytochrome c

Fluorochromatic quantification of FITC-conjugated cytochrome c antibodies in MCF-7 cells was conducted by means of flow cytometry analyses. Figure 11B shows a slight increase in FITC-conjugated cytochrome c in 2ME-treated cells when compared to the vehicle-treated control (Figure 11A-B). Statistical analyses indicated a significant 1.16±0.08-fold increase in FITC-conjugated cytochrome c in 2ME-treated cells over the vehicle-treated control (normalized to 1) (Figure 12). These results indicate that mitochondrial release of cytochrome c is slightly increased in 2ME-treated MCF-7 cells.
3.7. Gene expression - Microarray

Agilent’s Human 1A Oligonucleotide Microarray slides with more than 41 000 60-mer oligonucleotide human genes and transcripts were employed to collect genomic information on the mechanism of action of 2ME in MCF-7 cells. Spotfinding was conducted with Genepix Pro 6.1. Genes that were considered statistically significantly differentially expressed ($B$-value > 0) and upregulated or downregulated in 2ME-treated cells are summarized in Tables 2 and 3 respectively. 775 genes out of the 41 000 (1.89%) transcripts were included for further analyses. Mapping of differentially expressed genes to biochemical pathways and GO categories was performed using GENECODIS. The statistically significant differentially expressed genes ($B > 0$) were mapped to regulation of transcription, signal transduction, cell cycle, apoptosis, nucleosome assembly, reactive oxygen species metabolism, DNA repair, microtubule base movement, cell adhesion and ribosomal activity (Supplementary Tables 1 and 2).

4. Discussion

In the present study we have demonstrated the effects of 1 µM 2ME in MCF-7 cells after 24 h of exposure. 2ME treatment resulted in increased levels of cyclin B1. Similar results were obtained by Bhati et al. (2007) in MDA-MB-435 breast cells and Attalla et al. (1996) in Jurkat cells [6, 32]. Expression of genes associated with microtubule dynamics were affected in 2ME-treated cells. Kamath et al. (2006) demonstrated that suppression of microtubule dynamics (and not microtubule depolymerization) plays a key role in mitosis in 2ME-treated MCF-7 cells [9]. In the present study several genes involved in microtubule dynamics were downregulated in 2ME-treated cells. These genes include BUB3, SPC25, ASPM, CENPE, CENPJ, CENPT, CEP55, as well as tubulin alpha- and beta genes, while SPIN2B was upregulated. BUB3 is required for the establishment of efficient kinetochore-microtubule attachments before the completion of mitosis. SPC25 plays a role in proper execution of mitotic events associated with kinetochore components and ASPM promotes spindle organization [33-35]. CENPE is a motor protein that carries chromosomes toward the metaphase plate and contributes to the capture and stabilization of spindle microtubules by kinetochores [36]. CENPJ (CPAP) is responsible for maintaining centrosome integrity and normal spindle morphology during cell division [37]. Relatively little is known about the function of CENPT, CEP55 and SPIN2B genes, however, overexpression of SPIN1 has been implicated in induced cell cycle delay in metaphase and mitotic spindle defects [38].

Bhati et al. (2007) demonstrated that the APC is inhibited in response to 2 µM 2ME in MDA-MB-435 breast cells [6]. They further demonstrated that genes involved in mitotic checkpoint complex (MCC) signaling (including NIMA, Bub1, Mad2) were
upregulated and that APC activity might be inhibited as a result of increased MCC signaling [6]. The MCC ensures accurate segregation of mitotic chromosomes by delaying anaphase onset until each kinetochore has properly attached to the mitotic spindle [39]. The MCC is activated in response to mitotic microtubules unattached to kinetochores and the system converges to inhibit the activity of the anaphase promoting complex/cyclosome-cell division cycle 20 (APC/C-cdc20) complex [39-42]. Activated APC/C-cdc20 targets cyclin B1 for ubiquitination and allows for a cell to transit from metaphase to anaphase [43]. Increased levels of cyclin B1 observed in the present study can in part be explained by decreased activity of the APC/C-cdc20 complex induced by 2ME; possibly through MCC activation and downregulation of cdc20 expression. This would lead to decreased degradation of the cyclin B1 protein and an increase in intracellular cyclin B1 evident in the present study. The observations of decreased mRNA expression of cyclins B1 and B2, as well as cdc2 are consistent with the findings of Zoubine et al. (1999) who revealed a decrease in the expression of cdc2 and cyclin B1 genes in 1 µM 2ME-treated MCF-7 cells [10]. While cdc2 mRNA expression was decreased in 2ME-treated MCF-7 cells, van Zijl et al. (2008) and Attalla et al. (1996) showed that cdc2 activity was significantly increased in 1 µM 2ME-treated MCF-7 and Jurkat cells respectively [11, 32]. Increased cdc2 activity can be explained by increased levels of cyclin B1 since cdc2 requires intact cyclin B1 protein.

Cell cycle analyses revealed an increase in cells in the G2/M phase, as well as in the number of cells present in the sub-G1 phase. These results are consistent with the findings of experiments in other cell lines that indicated an accumulation of cells in the G2/M-phase in 2ME-treated cells [6, 44-46]. Active cyclin B1-cdc2 levels needed for mitotic entry are lower than active cyclin B1-cdc2 levels needed for mitotic progression [47]. The findings that 2ME treatment of MCF-7 leads to a decrease in cdc2 and cyclin B1 expression, but an increase in cyclin B1 protein levels and cdc2 activity further explains the mitotic block. A sufficient amount of cyclin B1-cdc2 may be enough for mitotic entry, but too low (as a result of decreased cdc2 and cyclin B1 expression) for mitotic progression in 2ME-treated cells [32]. Cdc2 regulates the activity of the APC/C-Cadherin 1 (APC/C-cdh1) complex through phosphorylation and subsequent prevention of APC/C association of cdh. The APC/C-cdh1 complex is responsible for the targeted degradation of securin and subsequent release of separase, which is responsible for cohesin cleavage to allow for sister chromatid separation and the onset of anaphase [48]. Elevated activity of cdc2 activity would thus abrogate the activity of the APC/C-cdh1 complex, resulting in cells in a G2/M arrest, as well as cells blocked in metaphase.

A marked decrease of cells in S-phase was also observed in 2ME-treated cells. A number of intra-S phase related checkpoint proteins involved in DNA repair were downregulated in 2ME-treated cells [49]. Genes of interest that play a role in DNA repair that were downregulated in 2ME-treated MCF-7 cells include ATR, BRCA1, DDB1, PARP1 and TOPBP1. Genes of proteins
constituting parts of the replisome (PCNA, RFC1 and RFC4) were also downregulated. Data obtained from gene expression analysis together with observations of an increase in the sub-G\(_1\) fraction and a decrease in the number of cells in the S-phase indicates that 2ME-treated cells are likely not to re-enter mitosis.

Generation of superoxide has previously been associated with 2ME treatment. Gao et al. (2005) observed an increase in superoxide generation in 4 \(\mu\)M 2ME-treated U937 human leukemia cells after 6 h treatment [50]. She et al. (2007) also observed an increase in superoxide levels in 2 \(\mu\)M 2ME-treated human myeloid leukemia HL-60 and U937 cells [51]. Chen et al. (2008) used a 0.1 mM 2ME concentration to induce superoxide generation in transformed HEK293, U87 and HeLa cancer cell lines [52]. Destruction of superoxide is catalyzed by manganese superoxide dismutase within the mitochondrial matrix and intracellular superoxide is destroyed by copper-zinc superoxide dismutase [53]. Kachadourian et al. demonstrated that 2ME (0.1 mM) does not inhibit superoxide dismutase and proposed the formation of estrogen semiquinone radicals with subsequent formation of superoxide [54-55]. The present study focused on a lower concentration of 2ME (1 \(\mu\)M) and no significant difference in superoxide levels between vehicle-treated and 2ME-treated cells was detected.

Generation of H\(_2\)O\(_2\) as a result of 2ME treatment has been implicated as a mediator of apoptosis induction. H\(_2\)O\(_2\) forms part of signal transduction pathways including the ERK, JNK and p38 pathways [56]. Fukui and Zhu (2009) demonstrated that 1.5-2 \(\mu\)M 2ME treatment of MDA-MB-435 breast cells induced activation of ERK, JNK and p38 proteins [13]. In Ewing sarcoma cells, 2ME-treated cells showed an increase in the formation of H\(_2\)O\(_2\) and rapid induction of the JNK pathway. This resulted in decreased mitochondrial membrane potential, release of cytochrome c and downstream activation of caspases [57]. The present study demonstrated an increase in H\(_2\)O\(_2\) generation in MCF-7 cells in response to 2ME treatment, as well as an increase in intracellular levels of cytochrome c. One possible source of H\(_2\)O\(_2\) is the inactivation of peroxiredoxin 1 (Prx 1). Prx 1 reduces H\(_2\)O\(_2\) to water and oxygen, and during mitosis activates cdc2 responsible for the phosphorylation and inactivation of the PRx 1 enzyme [58]. Thus, prolonged cdc2 activity during metaphase and subsequent elevation of H\(_2\)O\(_2\) may be due to PRx 1 inhibition. Another interesting finding is the upregulation of spermine oxidase (SMOX). SMOX is the only catabolic enzyme that is able to specifically oxidise spermine the spermidine [59-60]. The reaction results in the formation of H\(_2\)O\(_2\) [60]. In human breast cancer cells as well as mouse neuroblastoma cells, SMOX overexpression results in an antiproliferative effect as a result of oxidative stress [61-62]. Overexpression of SMOX as a result of 2ME treatment is thus another possible source of H\(_2\)O\(_2\). Differentially expressed genes associated with ROS-signaling include the upregulation of mitogen-activated protein kinase 4 (MKK4) and mitogen-activated
protein kinase 6 (MKK6). Heme oxygenase-1 (HO-1) was also upregulated in 2ME-treated MCF-7 cells and it is well known that HO-1 mRNA is strongly induced by H$_2$O$_2$ and ferric iron [63-65].

H$_2$O$_2$ and other ROS are known to activate several growth inhibitory pathways such as autophagy. Activation of autophagic processes is regulated through inactivation of mammalian target of rapamycin (mTOR) and Beclin 1. Active mTOR inhibits LC3 activity which is required for the formation process of autophagosomes [66]. In U937 leukemia cells, 4 µM 2ME gradually decreased mTOR and phospho-mTOR protein levels over time and catalase prevented this gradual decrease [50]. It was argued that H$_2$O$_2$, as well as superoxide formation are primarily responsible for these signaling events in U937 leukemia cells [50]. Recently it has been demonstrated that H$_2$O$_2$ and other ROS can induce autophagic processes through inhibition of the autophagy-related gene 4 (Atg4) as well as induction of Beclin 1 expression [67]. Chen et al. (2008) demonstrated that autophagic processes were induced in the HEK293 transformed cell line and the cancer cell lines U87 and HeLa [52]. They further demonstrated that these processes are caused as a result of H$_2$O$_2$ formation. In the present study, we have demonstrated an increase in acridine orange staining in 2ME-treated MCF-7 cells, as well as an increase in the formation of vacuoles. Increased acridine orange staining in cells is an indication of increased acidic vesicle formation and these are associated with increased lysosomal and/or autophagic processes [23]. Furthermore, gene expression analysis revealed the downregulation of eukaryotic translation initiation factors (EIFs) involved in mRNA translation and are controlled downstream of mTOR activity [66]. These include EIF4E, EIF4A2, EIF4B, EIF2C1 and EIF3S6. Several genes associated with ribosomal activity were also downregulated. Similar results were obtained by Bhati et al. (2007) where a decrease in the expression of ribosomal proteins and inhibition of protein translation was observed in 2ME-treated MDA-MB-435 cells [6]. Also, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase (PTEN) was slightly up-regulated in response to 2ME-treatment. PTEN overexpression is able to inhibit mTOR activity through the phosphoinositide 3-kinase/ protein kinase B/ tuberous sclerosis complex 2 (PI3K/Akt/TSC2) pathway [68]. mTOR inhibition plays a role in HIF-1α activity by preventing HIF-1α transcriptional activation and this in turn plays a role in the antiangiogenic effects of mTOR inhibitors [69-70]. Our results together with related findings from other studies suggest that autophagic processes are also activated in 2ME-treated MCF-7 cells through an mTOR-mediated pathway whereby ROS and PTEN overexpression are likely to play a role in abrogating the activity of mTOR.

Induction of apoptosis has been associated with 2ME treatment in various cell lines. JNK signaling and subsequent phosphorylation and inactivation of anti-apoptotic Bcl-2 proteins is a common mechanism of activating the intrinsic apoptosis pathway [13, 50, 57]. Early and late stages of apoptosis induction were observed in 2ME-treated MCF-7 cells. A slight increase in intracellular
cytochrome c formation was also demonstrated in 2ME-treated cells which indirectly indicate an increase in mitochondrial permeabilization, possibly due to inactivation of the anti-apoptotic Bcl-2 protein. Tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10/TRAIL) was also found to be upregulated. Upregulation of TNFSF10/TRAIL can in part explain the upregulation of death receptor 5 in 2ME-treated breast carcinoma cells MDA-MB-231 and MDA-MB-435, cervical carcinoma cells HeLa, prostate carcinoma cells PC-3, and glioma cells U87-MG cells [14]. MCF-7 cells, however, are deficient in caspase-3 expression and undergo apoptosis without showing inter-nucleosomal cleavages [71]. It is thus unlikely that cytochrome c release plays a significant role in apoptosis induction through caspase activation in MCF-7 cells. Gene expression analyses revealed the upregulation of proaprototic genes including BCL2 binding component 3, TP53INP1 tumor protein p53 inducible nuclear protein 1, cyclin-dependent kinase inhibitor 2A and calpastatin (CAST). v-Myc myelocytomatosis viral oncogene homolog (avian) (MYC) was found to be downregulated in 2ME-treated MCF-7 cells. The present study also revealed the downregulation of genes associated with nucleosome assembly, as well as cell adhesion.

From the data and presently available literature, it is thus proposed that interference with microtubule dynamics and subsequent activation of the MCC cause inhibition of cyclin B ubiquination and degradation, leading to increased cdc2 activity, a metaphase block and inactivation of PRx1 (Figure 13). Increased formation of ROS play a role in pro-apoptotic ROS signaling which results in the activation of growth inhibitory pathways including apoptosis and autophagy. In conclusion, 2ME treatment of MCF-7 cells resulted in increased cyclin B1 protein levels, cell cycle arrest, increased H$_2$O$_2$ formation, increased intracellular levels of cytochrome c and vacuole formation together with increased acidic vesicle formation. Gene expression analysis revealed that 2ME interferes with microtubule dynamics, mitotic checkpoint signaling, cyclin B1 degradation, cdc2 activity and pro-apoptotic events. Furthermore, microarray gene expression analysis showed a decreased expression of genes involved in mRNA translation and autophagy-related processes, including ribosomal proteins and EIFs. Thus, a novel finding namely the induction of both apoptosis and autophagy as a possible combination of types of cell death induced by 2ME in MCF-7 cells is suggested and therefore the present study contributes to the mechanism of its action.

**Acknowledgements**

This research was supported by grants from the Medical Research Council of South Africa (AG374, AK076), the Cancer Association of South Africa (AK246) and the Struwig-Germeshuysen Cancer Research Trust of South Africa (AJ038). Electron microscopy was conducted at the Electron microscopy Unit at the University of Pretoria and flow cytometric analyses were performed at the Department of Pharmacology at the Faculty of Health Sciences (University of Pretoria). Microarray data analysis
facilities were provided by the African Centre of Gene Technology (ACGT) Microarray Facility (University of Pretoria, Pretoria, South Africa) and the Bioinformatics and Computational Biology Unit (University of Pretoria, Pretoria, South Africa).

References


Figure Caption

**Figure 1:** FITC (FL1 Log) vs propidium iodide (FL3 Lin) dot-plot of vehicle-treated cells (A) and 1 µM 2ME-treated (B) MCF-7 cells after 24 h of exposure. FITC-conjugated isotypic control cells were normalized to 2% and subsequent readings were measured on the normalized plot. A marked increase in cyclin B1 levels is observed in the G2/M fraction of 2ME-treated cells when compared to the vehicle-treated control. Graphs are representative of 3 repeats.

**Figure 2:** Measurement of cyclin B1 FITC-positive MCF-7 cells. An increase of ±22% to 38±7% in G2/M cells was observed in 2ME-treated cells when compared to 16±3.7% in vehicle-treated cells. An asterisk (*) indicates a P-value < 0.05. Figures are representative of three repeats.
Figure 3: Cell cycle histograms (FL3 Log) of vehicle-treated control cells (A) and 1 µM 2ME-treated (B) MCF-7 cells after 24 h of exposure. A marked increase in the number of cells present in the sub-G₁ fraction is observed in 2ME-treated cells. The S-phase is more pronounced in the vehicle-treated control.

Figure 4: Distribution of DNA content in vehicle-treated and 1 µM 2ME-treated MCF-7 cells. A statistically significant increase in the G₂/M phase in 2ME-treated cells (23.07±1.7%) compared to vehicle-treated cells (19.3±0.9%) is observed. An asterisk (*) indicates a P-value < 0.05 when compared to the vehicle control.
Figure 5: DCFDA (FL1 Log) histogram of 1 μM 2ME-treated cells superimposed on the vehicle-treated control cells (set as control) in MCF-7 cells after 24 h of exposure. An increase in mean DCF fluorescence intensity (shift to the right) is observed in both 2ME-treated (A). B) Relative mean fluorescence intensity of vehicle-treated (normalized to 1), 1 μM 2ME-treated and 20 μM H₂O₂-treated cells. A 1.54±0.17-fold increase \( (P = 0.004) \) in mean fluorescence intensity in 2ME-treated cells and a 1.92±0.33-fold increase \( (P = 0.003) \) in H₂O₂-treated positive control was observed when compared to the vehicle-treated control. An asterisk (*) indicates a \( P\)-value < 0.05 when compared to vehicle control (B).

Figure 6: Hydroethidine (FL2 Log) histogram of 1 μM 2ME-treated cells superimposed on the vehicle-treated control cells (set as control) in MCF-7 cells after 24 h of exposure. No significant difference was observed (A). Relative mean fluorescence intensity of vehicle-treated (normalized to 1) and 1 μM 2ME-treated cells. A statistically insignificant \( (P = 0.6) \) 1.03-fold increase in mean fluorescence intensity in 2ME-treated cells was observed when compared to the vehicle-treated control (B).
Figure 7: Hoechst 33342-stained vehicle-treated (A), 1 µM 2ME-treated (B) and 0.2 µg/ml Actinomycin D-treated (C) MCF-7 cells after 24 h of exposure. Normal cycling cells in anaphase and met-anaphase are observed in the vehicle-treated control (A). Cells in metaphase and tripolar metaphase are observed in 2ME-treated cells (B). Actinomycin D-treated cells exhibit hallmarks of late stages of apoptosis including hypercondensed chromatin during apoptotic body formation (C).
Figure 8: Acridine orange-stained vehicle-treated (A), 1 µM 2ME-treated (B) and 0.2 µg/ml Actinomycin D-treated (C) MCF-7 cells after 24 h of exposure. Residual acridine orange staining (RAOS) is observed vehicle-treated cells. However, an increase in acridine orange staining is also observed in cells undergoing mitosis (A). An overall increase in acridine orange (IAOS) is observed in 2ME-treated cells (B), while cells undergoing late stages of apoptosis in Actinomycin D-treated cells have residual acridine orange staining (C).
Figure 9: Transmission electron micrographs of MCF-7-stained vehicle-treated (A), 1 µM 2ME-treated (B) and 0.2 µg/ml Actinomycin D-treated (C) MCF-7 cells after 24 h of exposure. Normal nuclear and cytoplasmic physiology is observed in vehicle-treated cells (A). 2ME-treated cells show an increase in the formation of vacuolar structures (B). Formation of apoptotic bodies and hypercondensed chromatin are observed in Actinomycin D-treated cells.
**Figure 10:** Propidium iodide (FL3 Log) vs Annexin V (FL1 Log) dot-plot of vehicle-treated (A) and 1 µM 2ME-treated (B) MCF-7 cells after 24 h of exposure. 2ME-treated cells show an increase in early and late stages of apoptosis when compared to vehicle-treated cells (A and B).

**Figure 11:** FITC (FL1 Log) histogram vehicle-treated control (A) and 1 µM 2ME-treated (B) MCF-7 cells. Intracellular cytochrome c levels are slightly increased in 2ME-treated cells when compared to the vehicle-treated control.
Figure 12: Relative mean fluorescence intensity of vehicle-treated (normalized to 1) and 1 µM 2ME treated MCF-7 cells. 2ME-treated cells exhibited a statistically significant 1.16±0.08-fold increase over the vehicle-treated control (normalized to 1).

Figure 13: Possible mechanisms of action in 2ME-treated MCF-7 cells. 1) 2ME interferes with microtubule dynamics, resulting in abrogated APC/C-cdc20 activity as a result of an active MCC signaling. 2) Decreased cyclin B degradation as a result of APC/C-cdc20 results in prolonged cyclin B/cdc2 activity. 3) Prolonged cyclin B/cdc2 activity inhibits APC/C-cdh1 activity and subsequent cohesion cleavage. 4) Prolonged cyclin B/cdc2 activity inhibits the activity of PRX1, thereby, contributing to ROS formation, resulting in increased and prolonged ROS signaling and subsequent cellular stress signaling cascades associated with growth inhibition and apoptosis.
Table Legends

**Table 1:** Measurement of phosphatidylserine externalization and membrane permeability of vehicle-treated, 1 μM 2ME-treated and 0.2 μg/ml Actinomycin D-treated MCF-7 cells after 24 h of exposure as an indication of cells in various stages of cell death. An increase in early and late stage of apoptosis was observed in 2ME-treated cells when compared to vehicle-treated cells. Late stages of apoptosis were not as pronounced in 2ME-treated cells when compared to Actinomycin D-treated cells.

<table>
<thead>
<tr>
<th>(mean %)</th>
<th>Vehicle control</th>
<th>1μM 2-methoxyestradiol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early apoptosis</td>
<td>2.66</td>
<td>11.14</td>
</tr>
<tr>
<td>Late apoptosis</td>
<td>1.52</td>
<td>3.95</td>
</tr>
<tr>
<td>Necrosis</td>
<td>0.95</td>
<td>0.34</td>
</tr>
<tr>
<td>Viable cells</td>
<td>94.87</td>
<td>84.57</td>
</tr>
</tbody>
</table>
**Supplementary Table 1:** Selected genes (gene name in brackets) upregulated in 24 h 2ME-treated MCF-7 cells revealed by amplified cRNA microarray and bioinformatics analyses.

<table>
<thead>
<tr>
<th>Agilent Reference number 44k</th>
<th>Description</th>
<th>log M (Diff expressed) Exposed - Control</th>
<th>B-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>45024 Cyclin-dependent kinase inhibitor 2A (CDKN2A) [NM_058197]</td>
<td>1.300</td>
<td>1.284</td>
<td></td>
</tr>
<tr>
<td>8598 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.474</td>
<td>3.943</td>
<td></td>
</tr>
<tr>
<td>15915 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.500</td>
<td>4.784</td>
<td></td>
</tr>
<tr>
<td>37339 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.517</td>
<td>2.244</td>
<td></td>
</tr>
<tr>
<td>19214 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.524</td>
<td>0.036</td>
<td></td>
</tr>
<tr>
<td>38829 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.538</td>
<td>4.183</td>
<td></td>
</tr>
<tr>
<td>14125 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.589</td>
<td>5.911</td>
<td></td>
</tr>
<tr>
<td>18594 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.594</td>
<td>2.075</td>
<td></td>
</tr>
<tr>
<td>14998 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) [NM_005194]</td>
<td>0.605</td>
<td>4.042</td>
<td></td>
</tr>
<tr>
<td>44942 FIIA-alpha/beta-like factor (ALF), transcript variant 2 [NM_172196]</td>
<td>1.078</td>
<td>1.022</td>
<td></td>
</tr>
<tr>
<td>31688 Estrogen-related receptor alpha (ESRRA), [NM_004451]</td>
<td>0.395</td>
<td>0.483</td>
<td></td>
</tr>
<tr>
<td>9238 Elongation factor, RNA polymerase II, 2 (ELL2), [NM_012081]</td>
<td>1.153</td>
<td>1.751</td>
<td></td>
</tr>
<tr>
<td>24662 Jun oncogene (JUN), [NM_002228]</td>
<td>0.696</td>
<td>4.513</td>
<td></td>
</tr>
<tr>
<td>3494 Jun oncogene (JUN), [NM_002228]</td>
<td>0.766</td>
<td>1.886</td>
<td></td>
</tr>
<tr>
<td>41956 Jun oncogene (JUN), [NM_002228]</td>
<td>0.768</td>
<td>5.459</td>
<td></td>
</tr>
<tr>
<td>22066 Jun oncogene (JUN), [NM_002228]</td>
<td>0.769</td>
<td>1.806</td>
<td></td>
</tr>
<tr>
<td>33732 Jun oncogene (JUN), [NM_002228]</td>
<td>0.774</td>
<td>4.070</td>
<td></td>
</tr>
<tr>
<td>14635 Myeloid/lymphoid or mixed-lineage leukemia (MLL) [AF272382]</td>
<td>0.187</td>
<td>0.490</td>
<td></td>
</tr>
<tr>
<td>26483 Nuclear factor (erythroid-derived 2)-like 1 (NFE2L1), [NM_003204]</td>
<td>0.316</td>
<td>2.219</td>
<td></td>
</tr>
<tr>
<td>795 BTB and CNC homology 1, basic leucine zipper transcription factor 1 (BACH1), transcript variant 1, [NM_206866]</td>
<td>0.389</td>
<td>0.600</td>
<td></td>
</tr>
<tr>
<td>18067 v-Rel reticuloendotheliosis viral oncogene homolog B, (RELB), [NM_006509]</td>
<td>0.533</td>
<td>3.030</td>
<td></td>
</tr>
<tr>
<td>42490 Tumor protein p53 (Li-Fraumeni syndrome) (TP53), [NM_000546]</td>
<td>1.656</td>
<td>1.547</td>
<td></td>
</tr>
<tr>
<td>42910 Tumor protein p53 (Li-Fraumeni syndrome) (TP53), [NM_000546]</td>
<td>1.799</td>
<td>1.616</td>
<td></td>
</tr>
<tr>
<td>40782 Nuclear receptor subfamily 2, group C, member 2 (NR2C2) [BC063441]</td>
<td>0.626</td>
<td>0.967</td>
<td></td>
</tr>
<tr>
<td>42912 CCHC-type zinc finger, nucleic acid binding protein (CNBP) [BU618765]</td>
<td>2.033</td>
<td>1.712</td>
<td></td>
</tr>
<tr>
<td>Gene Name</td>
<td>Description</td>
<td>Ratio 1</td>
<td>Ratio 2</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>GTF2I repeat domain containing 1 (GTF2IRD1), transcript variant 2, [NM_005685]</td>
<td>0.254</td>
<td>1.228</td>
<td></td>
</tr>
<tr>
<td>cAMP responsive element binding protein 5 (CREB5), transcript variant 1, [NM_182898]</td>
<td>0.670</td>
<td>2.291</td>
<td></td>
</tr>
<tr>
<td>Suppression of tumorigenicity 18 (ST18) [AF074982]</td>
<td>1.602</td>
<td>1.517</td>
<td></td>
</tr>
<tr>
<td>Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 (CITED2) [AW84496]</td>
<td>0.265</td>
<td>1.848</td>
<td></td>
</tr>
<tr>
<td>Catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1), [NM_001904]</td>
<td>0.254</td>
<td>0.251</td>
<td></td>
</tr>
<tr>
<td>Ephrin-B1 (EFNB1), [NM_004429]</td>
<td>0.305</td>
<td>2.904</td>
<td></td>
</tr>
<tr>
<td>Ephrin-B2 (EFNB2), [NM_004093]</td>
<td>0.489</td>
<td>5.298</td>
<td></td>
</tr>
<tr>
<td>EPH receptor A2 (EPHA2), [NM_004431]</td>
<td>0.313</td>
<td>0.367</td>
<td></td>
</tr>
<tr>
<td>EPH receptor A4 (EPHA4), [NM_004438]</td>
<td>1.312</td>
<td>8.536</td>
<td></td>
</tr>
<tr>
<td>Guanine nucleotide binding protein (GNAO1), transcript variant 2, [NM_138736]</td>
<td>0.180</td>
<td>0.596</td>
<td></td>
</tr>
<tr>
<td>Insulin-like growth factor 1 (somatomedin C) (IGF1), [NM_000618]</td>
<td>1.744</td>
<td>1.594</td>
<td></td>
</tr>
<tr>
<td>Mitogen-activated protein kinase 4 (MAPK4) [X59727]</td>
<td>0.264</td>
<td>2.045</td>
<td></td>
</tr>
<tr>
<td>Mitogen-activated protein kinase 6 (MAPK6), [NM_002748]</td>
<td>0.238</td>
<td>1.706</td>
<td></td>
</tr>
<tr>
<td>MAP kinase interacting serine/threonine kinase 2 (MKNK2), transcript variant 1, [NM_017572]</td>
<td>0.826</td>
<td>1.200</td>
<td></td>
</tr>
<tr>
<td>Vascular endothelial growth factor A (VEGFA), transcript variant 1, [NM_00125366]</td>
<td>0.377</td>
<td>3.235</td>
<td></td>
</tr>
<tr>
<td>Vascular endothelial growth factor A (VEGFA), transcript variant 1, [NM_00125366]</td>
<td>0.393</td>
<td>2.916</td>
<td></td>
</tr>
<tr>
<td>Vascular endothelial growth factor A (VEGFA), transcript variant 1, [NM_00125366]</td>
<td>0.397</td>
<td>1.026</td>
<td></td>
</tr>
<tr>
<td>Vascular endothelial growth factor A (VEGFA), transcript variant 1, [NM_00125366]</td>
<td>0.438</td>
<td>4.690</td>
<td></td>
</tr>
<tr>
<td>Wingless-type MMTV integration site family, member 5A (WNT5A), [NM_003392]</td>
<td>0.291</td>
<td>1.035</td>
<td></td>
</tr>
<tr>
<td>O-linked N-acetylglucosamine (GlcNAc) transferase (OGT), transcript variant 1, [NM_181672]</td>
<td>0.835</td>
<td>1.104</td>
<td></td>
</tr>
<tr>
<td>Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 (DYRK3), transcript variant 2, [NM_00100423]</td>
<td>0.960</td>
<td>6.152</td>
<td></td>
</tr>
<tr>
<td>RIO kinase 2 (yeast) (RIOK2), [NM_018343]</td>
<td>0.262</td>
<td>1.120</td>
<td></td>
</tr>
<tr>
<td>RIO kinase 2 (yeast) (RIOK2), [NM_018343]</td>
<td>0.291</td>
<td>1.176</td>
<td></td>
</tr>
<tr>
<td>RIO kinase 2 (yeast) (RIOK2), [NM_018343]</td>
<td>0.307</td>
<td>2.390</td>
<td></td>
</tr>
<tr>
<td>RIO kinase 2 (yeast) (RIOK2), [NM_018343]</td>
<td>0.336</td>
<td>1.651</td>
<td></td>
</tr>
<tr>
<td>RIO kinase 2 (yeast) (RIOK2), [NM_018343]</td>
<td>0.342</td>
<td>1.925</td>
<td></td>
</tr>
<tr>
<td>RIO kinase 3 (yeast) (RIOK3), transcript variant 2, [NM_145006]</td>
<td>0.750</td>
<td>6.199</td>
<td></td>
</tr>
<tr>
<td>Serine/threonine kinase 38 like (STK38L), [NM_015000]</td>
<td>0.355</td>
<td>4.038</td>
<td></td>
</tr>
<tr>
<td>Connector enhancer of kinase suppressor of Ras 1 (CNKSR1), [NM_006314]</td>
<td>0.207</td>
<td>0.806</td>
<td></td>
</tr>
<tr>
<td>Dual specificity phosphatase 1 (DUSP1), [NM_004417]</td>
<td>1.034</td>
<td>4.180</td>
<td></td>
</tr>
<tr>
<td>Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19kDa, alpha isoform (calcineurin B, type I) (PPP3R1), [NM_000945]</td>
<td>0.240</td>
<td>1.976</td>
<td></td>
</tr>
<tr>
<td>Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), [NM_000314]</td>
<td>0.184</td>
<td>0.441</td>
<td></td>
</tr>
<tr>
<td>Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), [NM_000314]</td>
<td>0.252</td>
<td>0.887</td>
<td></td>
</tr>
<tr>
<td>Protein/Protein Name</td>
<td>Accession</td>
<td>Fold Change</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), [NM_000314]</td>
<td>0.256</td>
<td>0.259</td>
<td></td>
</tr>
<tr>
<td>Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), [NM_000314]</td>
<td>0.263</td>
<td>1.208</td>
<td></td>
</tr>
<tr>
<td>HRAS-like suppressor 3 (HRASLS3), [NM_007069]</td>
<td>0.309</td>
<td>0.582</td>
<td></td>
</tr>
<tr>
<td>Suppressor of cytokine signaling 3 (SOCS3), [NM_003955]</td>
<td>0.270</td>
<td>1.926</td>
<td></td>
</tr>
<tr>
<td>SHC (Src homology 2 domain containing) transforming protein 1 (SHC1), transcript variant 2, [NM_003029]</td>
<td>1.070</td>
<td>1.010</td>
<td></td>
</tr>
<tr>
<td>Nemo-like kinase (NLK), [NM_016231]</td>
<td>0.229</td>
<td>0.545</td>
<td></td>
</tr>
<tr>
<td>phospholipase A2, group IIF (PLA2G2F), [NM_022819]</td>
<td>0.873</td>
<td>0.721</td>
<td></td>
</tr>
<tr>
<td>BAI1-associated protein 2 (BAIAP2), transcript variant 1, [NM_017450]</td>
<td>0.679</td>
<td>3.410</td>
<td></td>
</tr>
<tr>
<td>endothelin 1 (EDN1), mRNA [NM_001955]</td>
<td>0.64</td>
<td>5.92</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.41</td>
<td>14.90</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.45</td>
<td>14.70</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.45</td>
<td>10.57</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.47</td>
<td>14.93</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.49</td>
<td>14.81</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.50</td>
<td>11.85</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.50</td>
<td>13.78</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.52</td>
<td>14.86</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.54</td>
<td>14.54</td>
<td></td>
</tr>
<tr>
<td>Interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_000600]</td>
<td>1.56</td>
<td>15.30</td>
<td></td>
</tr>
<tr>
<td>Cyclin-dependent kinase inhibitor 2A (CDKN2A) [NM_058197]</td>
<td>1.300</td>
<td>1.284</td>
<td></td>
</tr>
<tr>
<td>Septin 1 (SEPT1) [AK056275]</td>
<td>0.526</td>
<td>2.720</td>
<td></td>
</tr>
<tr>
<td>Septin 2 (SEPT2), transcript variant 1, [NM_001008491]</td>
<td>1.124</td>
<td>1.085</td>
<td></td>
</tr>
<tr>
<td>Spindlin family, member 2B (SPIN2B), transcript variant 3, [NM_001006683]</td>
<td>0.367</td>
<td>2.934</td>
<td></td>
</tr>
<tr>
<td>Regulator of G-protein signalling 2, 24kDa (RGS2), [NM_002923]</td>
<td>0.460</td>
<td>2.620</td>
<td></td>
</tr>
<tr>
<td>Cell division cycle 40 homolog (S. cerevisiae) (CDC40), [NM_015891]</td>
<td>0.415</td>
<td>3.522</td>
<td></td>
</tr>
<tr>
<td>Transducer of ERBB2, 1 (TOB1), [NM_005749]</td>
<td>0.832</td>
<td>2.475</td>
<td></td>
</tr>
<tr>
<td>Transducer of ERBB2, 2 (TOB2), [NM_016272]</td>
<td>0.167</td>
<td>0.355</td>
<td></td>
</tr>
<tr>
<td>BCL2 binding component 3 (BBC3) (PUMA), [NM_014417]</td>
<td>2.623</td>
<td>7.464</td>
<td></td>
</tr>
<tr>
<td>TP53INP1 tumor protein p53 inducible nuclear protein 1 (TP53INP1) [AK001057]</td>
<td>1.154</td>
<td>1.124</td>
<td></td>
</tr>
<tr>
<td>Inositol hexaphosphate kinase 2 (HPK2), transcript variant 3, [NM_001005910]</td>
<td>0.749</td>
<td>2.538</td>
<td></td>
</tr>
<tr>
<td>Calpastatin (CAST), transcript variant 1, mRNA [NM_001750]</td>
<td>0.279</td>
<td>2.343</td>
<td></td>
</tr>
</tbody>
</table>

**Cell Cycle**

<table>
<thead>
<tr>
<th>Protein/Protein Name</th>
<th>Accession</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin-dependent kinase inhibitor 2A (CDKN2A) [NM_058197]</td>
<td>1.300</td>
<td>1.284</td>
</tr>
<tr>
<td>Septin 1 (SEPT1) [AK056275]</td>
<td>0.526</td>
<td>2.720</td>
</tr>
<tr>
<td>Septin 2 (SEPT2), transcript variant 1, [NM_001008491]</td>
<td>1.124</td>
<td>1.085</td>
</tr>
<tr>
<td>Spindlin family, member 2B (SPIN2B), transcript variant 3, [NM_001006683]</td>
<td>0.367</td>
<td>2.934</td>
</tr>
<tr>
<td>Regulator of G-protein signalling 2, 24kDa (RGS2), [NM_002923]</td>
<td>0.460</td>
<td>2.620</td>
</tr>
<tr>
<td>Cell division cycle 40 homolog (S. cerevisiae) (CDC40), [NM_015891]</td>
<td>0.415</td>
<td>3.522</td>
</tr>
<tr>
<td>Transducer of ERBB2, 1 (TOB1), [NM_005749]</td>
<td>0.832</td>
<td>2.475</td>
</tr>
<tr>
<td>Transducer of ERBB2, 2 (TOB2), [NM_016272]</td>
<td>0.167</td>
<td>0.355</td>
</tr>
</tbody>
</table>

**Apoptosis**

<table>
<thead>
<tr>
<th>Protein/Protein Name</th>
<th>Accession</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCL2 binding component 3 (BBC3) (PUMA), [NM_014417]</td>
<td>2.623</td>
<td>7.464</td>
</tr>
<tr>
<td>TP53INP1 tumor protein p53 inducible nuclear protein 1 (TP53INP1) [AK001057]</td>
<td>1.154</td>
<td>1.124</td>
</tr>
<tr>
<td>Inositol hexaphosphate kinase 2 (HPK2), transcript variant 3, [NM_001005910]</td>
<td>0.749</td>
<td>2.538</td>
</tr>
<tr>
<td>Calpastatin (CAST), transcript variant 1, mRNA [NM_001750]</td>
<td>0.279</td>
<td>2.343</td>
</tr>
</tbody>
</table>
### Nucleosome assembly

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene Name</th>
<th>Symbol</th>
<th>NM accession</th>
<th>Expression</th>
<th>Log2 Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>22940</td>
<td>Histone cluster 1, H2bh (HIST1H2BH)</td>
<td>[NM_003524]</td>
<td>0.568</td>
<td>5.780</td>
<td></td>
</tr>
<tr>
<td>26132</td>
<td>Histone cluster 1, H2bl (HIST1H2BL)</td>
<td>[NM_003519]</td>
<td>0.555</td>
<td>4.875</td>
<td></td>
</tr>
<tr>
<td>15833</td>
<td>Histone cluster 1, H2bo (HIST1H2BO)</td>
<td>[NM_003527]</td>
<td>0.563</td>
<td>5.763</td>
<td></td>
</tr>
<tr>
<td>18518</td>
<td>Histone cluster 2, H2aa4 (HIST2H2AA4)</td>
<td>[NM_001040874]</td>
<td>0.394</td>
<td>4.031</td>
<td></td>
</tr>
<tr>
<td>40397</td>
<td>DOT1-like, histone H3 methyltransferase (S. cerevisiae) (DOT1L)</td>
<td>[NM_032482]</td>
<td>0.231</td>
<td>0.506</td>
<td></td>
</tr>
</tbody>
</table>

### Reactive oxygen species metabolism

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene Name</th>
<th>Symbol</th>
<th>NM accession</th>
<th>Expression</th>
<th>Log2 Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>18169</td>
<td>Sequestosome 1 (SQSTM1)</td>
<td>[U46752]</td>
<td>1.239</td>
<td>7.238</td>
<td></td>
</tr>
<tr>
<td>43478</td>
<td>Heme oxygenase (decycling) 1 (HMOX1)</td>
<td>[NM_002133]</td>
<td>0.418</td>
<td>0.605</td>
<td></td>
</tr>
<tr>
<td>42685</td>
<td>Heme oxygenase (decycling) 1 (HMOX1)</td>
<td>[NM_002133]</td>
<td>0.437</td>
<td>4.826</td>
<td></td>
</tr>
<tr>
<td>40823</td>
<td>Heme oxygenase (decycling) 1 (HMOX1)</td>
<td>[NM_002133]</td>
<td>0.462</td>
<td>3.509</td>
<td></td>
</tr>
<tr>
<td>20842</td>
<td>Heme oxygenase (decycling) 1 (HMOX1)</td>
<td>[NM_002133]</td>
<td>0.517</td>
<td>3.501</td>
<td></td>
</tr>
<tr>
<td>29347</td>
<td>Heme oxygenase (decycling) 1 (HMOX1)</td>
<td>[NM_002133]</td>
<td>0.550</td>
<td>4.903</td>
<td></td>
</tr>
<tr>
<td>28433</td>
<td>Glutathione S-transferase pi (GSTP1)</td>
<td>[NM_000852]</td>
<td>0.333</td>
<td>1.710</td>
<td></td>
</tr>
<tr>
<td>14586</td>
<td>Cytochrome P450, family 4, subfamily F, polypeptide 8 (CYP4F8)</td>
<td>[NM_175839]</td>
<td>0.301</td>
<td>2.583</td>
<td></td>
</tr>
<tr>
<td>38810</td>
<td>Spermine oxidase (SMOX)</td>
<td>[NM_175839]</td>
<td>0.712</td>
<td>4.627</td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Table 2: Selected genes (gene name in brackets) downregulated in 24 h 2ME-treated MCF-7 cells revealed by amplified cRNA microarray and bioinformatics analyses.

<table>
<thead>
<tr>
<th>Agilent Reference number 44k</th>
<th>Description</th>
<th>log M (Diff expressed) Exposed - Control</th>
<th>B-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>32943</td>
<td>PC4 and SFRS1 interacting protein 1 (PSIP1), transcript variant 2, [NM_033222]</td>
<td>-0.419</td>
<td>3.554</td>
</tr>
<tr>
<td>5222</td>
<td>PC4 and SFRS1 interacting protein 1 (PSIP1), transcript variant 1, [NM_021144]</td>
<td>-0.372</td>
<td>3.338</td>
</tr>
<tr>
<td>24763</td>
<td>E2F transcription factor 1 (E2F1), [NM_005225]</td>
<td>-0.382</td>
<td>0.628</td>
</tr>
<tr>
<td>8463</td>
<td>E2F transcription factor 1 (E2F1), [NM_005225]</td>
<td>-0.380</td>
<td>2.232</td>
</tr>
<tr>
<td>24063</td>
<td>E2F transcription factor 1 (E2F1), [NM_005225]</td>
<td>-0.357</td>
<td>3.102</td>
</tr>
<tr>
<td>40655</td>
<td>E2F transcription factor 1 (E2F1), [NM_005225]</td>
<td>-0.288</td>
<td>2.830</td>
</tr>
<tr>
<td>27072</td>
<td>Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), [NM_001402]</td>
<td>-0.411</td>
<td>2.174</td>
</tr>
<tr>
<td>28804</td>
<td>Eukaryotic translation initiation factor 2C, 1 (EIF2C1), [NM_012199]</td>
<td>-0.236</td>
<td>1.189</td>
</tr>
<tr>
<td>24898</td>
<td>Eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), [NM_001967]</td>
<td>-0.269</td>
<td>2.271</td>
</tr>
<tr>
<td>2014</td>
<td>Eukaryotic translation initiation factor 3, subunit 6 48kDa (EIF3S6), mRNA [NM_001568]</td>
<td>-0.35</td>
<td>0.34</td>
</tr>
<tr>
<td>32368</td>
<td>Eukaryotic translation initiation factor 4B (EIF4B), mRNA [NM_001417]</td>
<td>-0.29</td>
<td>2.11</td>
</tr>
<tr>
<td>5425</td>
<td>Eukaryotic translation initiation factor 4E (EIF4E), [NM_001968]</td>
<td>-0.221</td>
<td>1.467</td>
</tr>
<tr>
<td>32010</td>
<td>Eukaryotic translation initiation factor 4E (EIF4E), [NM_001968]</td>
<td>-0.178</td>
<td>0.742</td>
</tr>
<tr>
<td>41986</td>
<td>Uveal autoantigen with coiled-coil domains and ankyrin repeats (UACA), transcript variant 2, [NM_001008224]</td>
<td>-0.319</td>
<td>3.362</td>
</tr>
<tr>
<td>36386</td>
<td>Ubiquitin carboxy-terminal hydrolase L5 (UCHL5), [NM_015984]</td>
<td>-0.359</td>
<td>0.418</td>
</tr>
<tr>
<td>15643</td>
<td>Ubiquitin carboxy-terminal hydrolase L5 (UCHL5), [NM_015984]</td>
<td>-0.299</td>
<td>0.915</td>
</tr>
<tr>
<td>37541</td>
<td>Ubiquitin carboxy-terminal hydrolase L5 (UCHL5), [NM_015984]</td>
<td>-0.294</td>
<td>2.441</td>
</tr>
<tr>
<td>15455</td>
<td>Ubiquitin-like, containing PHD and RING finger domains, 1 (UHRF1), transcript variant 2, [NM_013282]</td>
<td>-0.971</td>
<td>4.684</td>
</tr>
<tr>
<td>36133</td>
<td>Ubiquitin specific peptidase 1 (USP1), transcript variant 1, [NM_003368]</td>
<td>-0.668</td>
<td>2.778</td>
</tr>
<tr>
<td>14676</td>
<td>Ubiquitin specific peptidase 10 (USP10), [NM_005153]</td>
<td>-0.226</td>
<td>1.210</td>
</tr>
<tr>
<td>20127</td>
<td>MCM5 minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) (MCM5), [NM_006739]</td>
<td>-0.910</td>
<td>5.014</td>
</tr>
<tr>
<td>31965</td>
<td>MCM5 minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) (MCM5), [NM_006739]</td>
<td>-0.813</td>
<td>1.225</td>
</tr>
<tr>
<td>41299</td>
<td>v-Myc myeloblastosis viral oncogene homolog (avian)-like 1 (MYBL1) [NM_00108041]</td>
<td>-0.226</td>
<td>0.535</td>
</tr>
<tr>
<td>31076</td>
<td>v-Myc myeloblastosis viral oncogene homolog (avian)-like 1 (MYBL1) [NM_00108041]</td>
<td>-0.226</td>
<td>0.932</td>
</tr>
<tr>
<td>10057</td>
<td>B-cell CLL/lymphoma 11A (zinc finger protein) (BCL11A), transcript variant 5, [NM_138553]</td>
<td>-0.505</td>
<td>4.373</td>
</tr>
<tr>
<td>36848</td>
<td>Methyl-CpG binding domain protein 3 (MBD3), [NM_003926]</td>
<td>-0.153</td>
<td>0.002</td>
</tr>
<tr>
<td>Gene ID</td>
<td>Description</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22826</td>
<td>Retinoblastoma 1 (including osteosarcoma) (RB1), [NM_000321]</td>
<td>-0.277</td>
<td>1.467</td>
</tr>
<tr>
<td>27682</td>
<td>Replication factor C (activator 1) 1, 145kDa (RFC1), [NM_002913]</td>
<td>-0.391</td>
<td>1.398</td>
</tr>
<tr>
<td>42983</td>
<td>Replication factor C (activator 1) 4, 37kDa (RFC4), transcript variant 1, [NM_002916]</td>
<td>-0.829</td>
<td>1.303</td>
</tr>
<tr>
<td>6967</td>
<td>TAF4 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 135kDa (TAF4), [NM_003185]</td>
<td>-0.329</td>
<td>0.598</td>
</tr>
<tr>
<td>44813</td>
<td>Poly(A) binding protein interacting protein 1 (PAIP1), transcript variant 1, [NM_006451]</td>
<td>-0.953</td>
<td>1.219</td>
</tr>
<tr>
<td>28023</td>
<td>MYC associated factor X (MAX), transcript variant 3, [NM_145113]</td>
<td>-0.256</td>
<td>0.543</td>
</tr>
<tr>
<td>35375</td>
<td>Estrogen-related receptor gamma (ESRRG), transcript variant 2, [NM_206594]</td>
<td>-0.294</td>
<td>3.138</td>
</tr>
</tbody>
</table>

**Signal Transduction**

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19167</td>
<td>Dedicator of cytokinesis 1 (DOCK1), [NM_001380]</td>
</tr>
<tr>
<td>19556</td>
<td>Fibroblast growth factor 13 (FGF13), transcript variant 1A, [NM_004114]</td>
</tr>
<tr>
<td>6311</td>
<td>Insulin receptor substrate 1 (IRS1), [NM_005544]</td>
</tr>
<tr>
<td>31718</td>
<td>Inositol 1,4,5-trisphosphate 3/6 kinase (ITPK1), [NM_014216]</td>
</tr>
<tr>
<td>32151</td>
<td>Nuclear receptor subfamily 2, group F, member 2 (NR2F2), [NM_021005]</td>
</tr>
<tr>
<td>12661</td>
<td>Protein kinase C, alpha (PRKCA), [NM_002737]</td>
</tr>
<tr>
<td>11864</td>
<td>Serum/glucocorticoid regulated kinase (SGK), [NM_005627]</td>
</tr>
<tr>
<td>13333</td>
<td>RAS-like, estrogen-regulated, growth inhibitor (RERG), [NM_032918]</td>
</tr>
</tbody>
</table>

**Cell Cycle**

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17390</td>
<td>Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) (CDKN2D), transcript variant 1, [NM_001800]</td>
</tr>
<tr>
<td>1100</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
</tr>
<tr>
<td>6249</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
</tr>
<tr>
<td>40847</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
</tr>
<tr>
<td>41436</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
</tr>
<tr>
<td>1896</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
</tr>
<tr>
<td>6165</td>
<td>Centromere protein J (CENPJ), [NM_018451]</td>
</tr>
<tr>
<td>38539</td>
<td>Centromere protein T (CENPT), [NM_025082]</td>
</tr>
<tr>
<td>8545</td>
<td>Centrosomal protein 55kDa (CEP55), [NM_018131]</td>
</tr>
<tr>
<td>3846</td>
<td>Abnormal spindle homolog, microcephaly associated (Drosophila) (ASPM), [NM_018136]</td>
</tr>
<tr>
<td>24997</td>
<td>Protein phosphatase 1, catalytic subunit, gamma isoform</td>
</tr>
<tr>
<td>12005</td>
<td>Anaphase promoting complex subunit 1 (ANAPC1), [NM_022662]</td>
</tr>
<tr>
<td>6731</td>
<td>Cyclin A2 (CCNA2), [NM_001237]</td>
</tr>
<tr>
<td>566</td>
<td>Cyclin A2 (CCNA2), [NM_001237]</td>
</tr>
<tr>
<td>11025</td>
<td>Cyclin B1 (CCNB1), [NM_031966]</td>
</tr>
<tr>
<td>38205</td>
<td>Cyclin B2 (CCNB2), [NM_004701]</td>
</tr>
<tr>
<td>32992</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>4502</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>40958</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>ID</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>24761</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>30680</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>2213</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>22913</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>6646</td>
<td>Cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, [NM_001786]</td>
</tr>
<tr>
<td>22672</td>
<td>Cell division cycle 20 homolog (S. cerevisiae) (CDC20), [NM_001255]</td>
</tr>
<tr>
<td>14751</td>
<td>Protein kinase, membrane associated tyrosine/threonine 1 (PKMYT1), transcript variant 2, [NM_182687]</td>
</tr>
<tr>
<td>32202</td>
<td>Nucleolar and spindle associated protein 1 (NUSAP1), transcript variant 1, [NM_016359]</td>
</tr>
<tr>
<td>20178</td>
<td>Microspherule protein 1 (MCRS1), transcript variant 1, [NM_006337]</td>
</tr>
<tr>
<td>42448</td>
<td>Histone cluster 1, H1b (HIST1H1B), [NM_005322]</td>
</tr>
<tr>
<td>21290</td>
<td>Histone cluster 1, H2ae (HIST1H2AE), [NM_021052]</td>
</tr>
<tr>
<td>25240</td>
<td>Histone cluster 1, H2ag (HIST1H2AG), [NM_021064]</td>
</tr>
<tr>
<td>20103</td>
<td>Histone cluster 1, H2ah (HIST1H2AH), [NM_080596]</td>
</tr>
<tr>
<td>34623</td>
<td>Histone cluster 1, H2aj (HIST1H2AJ), [NM_021066]</td>
</tr>
<tr>
<td>27286</td>
<td>Histone cluster 1, H2bc (HIST1H2BC), [NM_003526]</td>
</tr>
<tr>
<td>37697</td>
<td>Histone cluster 1, H2bd (HIST1H2BD), transcript variant 1, [NM_021063]</td>
</tr>
<tr>
<td>16927</td>
<td>Histone cluster 1, H2bj (HIST1H2BJ), [NM_021058]</td>
</tr>
<tr>
<td>38808</td>
<td>Histone cluster 1, H3b (HIST1H3B), [NM_003537]</td>
</tr>
<tr>
<td>7672</td>
<td>Histone cluster 1, H3d (HIST1H3D), [NM_003530]</td>
</tr>
<tr>
<td>33910</td>
<td>Histone cluster 1, H3f (HIST1H3F), [NM_021018]</td>
</tr>
<tr>
<td>26742</td>
<td>Histone cluster 1, H3g (HIST1H3G), [NM_003534]</td>
</tr>
<tr>
<td>35067</td>
<td>Histone cluster 1, H3h (HIST1H3H), [NM_003536]</td>
</tr>
<tr>
<td>17437</td>
<td>Histone cluster 1, H3j (HIST1H3J), [NM_003535]</td>
</tr>
<tr>
<td>5363</td>
<td>Histone cluster 1, H4b (HIST1H4B), [NM_003544]</td>
</tr>
<tr>
<td>32961</td>
<td>Histone cluster 1, H4j (HIST1H4J), [NM_003495]</td>
</tr>
<tr>
<td>36101</td>
<td>Histone cluster 1, H4j (HIST1H4J), [NM_021968]</td>
</tr>
<tr>
<td>36856</td>
<td>Histone cluster 2, H2ab (HIST2H2AB), [NM_175065]</td>
</tr>
<tr>
<td>13219</td>
<td>Histone cluster 2, H2ac (HIST2H2AC), [NM_003517]</td>
</tr>
<tr>
<td>21511</td>
<td>Histone cluster 2, H3, pseudogene 2 (HIST2H3PS2), [NM_001025303]</td>
</tr>
<tr>
<td>Gene Name</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Histone cluster 2, H3, pseudogene 2 (HIST2H3PS2), [NM_001025303]</td>
<td>-0.345</td>
</tr>
<tr>
<td>Histone cluster 2, H4b (HIST2H4B), [NM_001034077]</td>
<td>-0.610</td>
</tr>
<tr>
<td>Histone cluster 3, H2a (HIST3H2A), [NM_033445]</td>
<td>-0.443</td>
</tr>
<tr>
<td>H2A Histone family, member J (H2AFJ), transcript variant 2, [NM_177925]</td>
<td>-0.375</td>
</tr>
<tr>
<td>H3 Histone, family 3A (H3F3A), [NM_002107]</td>
<td>-0.258</td>
</tr>
<tr>
<td>MutY homolog (E. coli) (MUTYH), transcript variant alpha1, [NM_012222]</td>
<td>-0.240</td>
</tr>
<tr>
<td>Ataxia telangiectasia and Rad3 related (ATR), [NM_001184]</td>
<td>-0.534</td>
</tr>
<tr>
<td>Breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, [NM_007295]</td>
<td>-0.565</td>
</tr>
<tr>
<td>Breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, [NM_007295]</td>
<td>-0.433</td>
</tr>
<tr>
<td>Breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, [NM_007295]</td>
<td>-0.421</td>
</tr>
<tr>
<td>Breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, [NM_007295]</td>
<td>-0.420</td>
</tr>
<tr>
<td>Breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, [NM_007295]</td>
<td>-0.393</td>
</tr>
<tr>
<td>Breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, [NM_007295]</td>
<td>-0.384</td>
</tr>
<tr>
<td>Structural maintenance of chromosomes 1A (SMC1A), [NM_006306]</td>
<td>-0.770</td>
</tr>
<tr>
<td>Damage-specific DNA binding protein 1, 127kDa (DDB1), [NM_001923]</td>
<td>-0.179</td>
</tr>
<tr>
<td>Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta) (PPP3CB), [NM_021132]</td>
<td>-0.210</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.968</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.945</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.938</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.923</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.921</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.920</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.910</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.899</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.892</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA), transcript variant 1, [NM_002592]</td>
<td>-0.892</td>
</tr>
<tr>
<td>Topoisomerase (DNA) II binding protein 1 (TOPBP1), [NM_007027]</td>
<td>-0.415</td>
</tr>
<tr>
<td>X-ray repair complementing defective repair in Chinese hamster cells 6 (Ku autoantigen, 70kDa) (XRCC6), [NM_001469]</td>
<td>-0.166</td>
</tr>
<tr>
<td>Poly (ADP-ribose) polymerase family, member 1 (PARP1), [NM_001618]</td>
<td>-0.177</td>
</tr>
<tr>
<td>Non-POU domain containing, octamer-binding (NONO), [NM_007363]</td>
<td>-0.313</td>
</tr>
<tr>
<td>Ubiquitin specific peptidase 1 (USP1), transcript variant 1, [NM_003368]</td>
<td>-0.668</td>
</tr>
<tr>
<td>Ubiquitin specific peptidase 10 (USP10), [NM_005153]</td>
<td>-0.226</td>
</tr>
<tr>
<td>Polymerase (DNA directed), delta 1, catalytic subunit 125kDa (POLD1), [NM_002691]</td>
<td>-0.717</td>
</tr>
<tr>
<td>Polymerase (DNA directed), epsilon 3 (p17 subunit) (POLE3), [NM_017443]</td>
<td>-0.587</td>
</tr>
<tr>
<td>ID</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>32625</td>
<td>RecQ protein-like 4 (RECQL4), [NM_004260]</td>
</tr>
</tbody>
</table>

**Microtubule Dynamics**

<table>
<thead>
<tr>
<th>ID</th>
<th>Description</th>
<th>Gene Accession</th>
<th>Fold Change</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>35421</td>
<td>BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) (BUB3), transcript variant 2, [NM_001007793]</td>
<td></td>
<td>-1.095</td>
<td>6.653</td>
</tr>
<tr>
<td>22718</td>
<td>BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) (BUB3), transcript variant 2, [NM_001007793]</td>
<td></td>
<td>-0.880</td>
<td>7.433</td>
</tr>
<tr>
<td>6050</td>
<td>BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) (BUB3), transcript variant 1, [NM_004725]</td>
<td></td>
<td>-0.323</td>
<td>0.778</td>
</tr>
<tr>
<td>26919</td>
<td>Echinoderm microtubule associated protein like 4 (EML4), [NM_019063]</td>
<td></td>
<td>-0.392</td>
<td>4.335</td>
</tr>
<tr>
<td>32472</td>
<td>Tubulin, alpha 1 (TUBA1), [NM_006000]</td>
<td></td>
<td>-0.486</td>
<td>1.851</td>
</tr>
<tr>
<td>15050</td>
<td>Tubulin, alpha 3 (TUBA3), [NM_006009]</td>
<td></td>
<td>-0.789</td>
<td>4.950</td>
</tr>
<tr>
<td>20071</td>
<td>Tubulin, alpha 6 (TUBA6), [NM_032704]</td>
<td></td>
<td>-1.151</td>
<td>8.030</td>
</tr>
<tr>
<td>24376</td>
<td>Tubulin, alpha 6 (TUBA6), [NM_032704]</td>
<td></td>
<td>-0.871</td>
<td>0.107</td>
</tr>
<tr>
<td>41243</td>
<td>Tubulin, alpha 8 (TUBA8), [NM_018943]</td>
<td></td>
<td>-0.475</td>
<td>0.296</td>
</tr>
<tr>
<td>21499</td>
<td>Tubulin, beta (TUBB), [NM_178014]</td>
<td></td>
<td>-0.844</td>
<td>4.333</td>
</tr>
<tr>
<td>36881</td>
<td>Tubulin, beta (TUBB), [NM_178014]</td>
<td></td>
<td>-0.764</td>
<td>4.013</td>
</tr>
<tr>
<td>1048</td>
<td>Tubulin, beta 2A (TUBB2A), [NM_001069]</td>
<td></td>
<td>-0.978</td>
<td>6.265</td>
</tr>
<tr>
<td>23995</td>
<td>Tubulin, beta 2C (TUBB2C), [NM_006088]</td>
<td></td>
<td>-1.518</td>
<td>4.671</td>
</tr>
<tr>
<td>35905</td>
<td>Tubulin, beta 6 (TUBB6), [NM_032525]</td>
<td></td>
<td>-0.776</td>
<td>3.683</td>
</tr>
<tr>
<td>42579</td>
<td>Dynein, cytoplasmic 2, heavy chain 1, (cDNA clone IMAGE:5265846), complete cds. [BC037496]</td>
<td></td>
<td>-0.201</td>
<td>1.240</td>
</tr>
<tr>
<td>2757</td>
<td>Microtubule-associated protein 7 (MAP7), [NM_003980]</td>
<td></td>
<td>-0.276</td>
<td>0.196</td>
</tr>
<tr>
<td>1100</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
<td></td>
<td>-0.539</td>
<td>1.461</td>
</tr>
<tr>
<td>6249</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
<td></td>
<td>-0.382</td>
<td>0.709</td>
</tr>
<tr>
<td>40847</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
<td></td>
<td>-0.373</td>
<td>3.133</td>
</tr>
<tr>
<td>41436</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
<td></td>
<td>-0.369</td>
<td>3.382</td>
</tr>
<tr>
<td>1896</td>
<td>Centromere protein E, 312kDa (CENPE), [NM_001813]</td>
<td></td>
<td>-0.226</td>
<td>1.655</td>
</tr>
<tr>
<td>6165</td>
<td>Centromere protein J (CENPJ), [NM_018451]</td>
<td></td>
<td>-0.450</td>
<td>1.365</td>
</tr>
<tr>
<td>38539</td>
<td>Centromere protein T (CENPT), [NM_025082]</td>
<td></td>
<td>-0.281</td>
<td>2.771</td>
</tr>
<tr>
<td>8545</td>
<td>Centrosomal protein 55kDa (CEP55), [NM_018131]</td>
<td></td>
<td>-0.531</td>
<td>5.301</td>
</tr>
<tr>
<td>8545</td>
<td>Centrosomal protein 55kDa (CEP55), [NM_018131]</td>
<td></td>
<td>-0.531</td>
<td>5.301</td>
</tr>
<tr>
<td>972</td>
<td>Spindle pole body component 25 homolog (S. cerevisiae) (SPBC25), [NM_020675]</td>
<td></td>
<td>-0.88056</td>
<td>6.770142</td>
</tr>
</tbody>
</table>

**Cell Adhesion**

<table>
<thead>
<tr>
<th>ID</th>
<th>Description</th>
<th>Gene Accession</th>
<th>Fold Change</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>11832</td>
<td>Collagen, type XI, alpha 1 (COL11A1), transcript variant B, [NM_080629]</td>
<td></td>
<td>-1.040</td>
<td>2.332</td>
</tr>
<tr>
<td>6206</td>
<td>Fibronectin 1 (FN1), transcript variant 1, [NM_212482]</td>
<td></td>
<td>-0.601</td>
<td>0.214</td>
</tr>
<tr>
<td>3974</td>
<td>Fibronectin 1 (FN1), transcript variant 1, [NM_212482]</td>
<td></td>
<td>-0.535</td>
<td>3.405</td>
</tr>
<tr>
<td>11780</td>
<td>Fibronectin 1 (FN1), transcript variant 1, [NM_212482]</td>
<td></td>
<td>-0.531</td>
<td>0.923</td>
</tr>
<tr>
<td>5497</td>
<td>Fibronectin 1 (FN1), transcript variant 1, [NM_212482]</td>
<td></td>
<td>-0.500</td>
<td>2.560</td>
</tr>
<tr>
<td>Gene ID</td>
<td>Description</td>
<td>Value1</td>
<td>Value2</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------</td>
<td>--------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>4212</td>
<td>Lysyl oxidase-like 2 (LOXL2), [NM_002318]</td>
<td>-0.405</td>
<td>3.613</td>
<td></td>
</tr>
<tr>
<td>33771</td>
<td>Lysyl oxidase-like 2 (LOXL2), [NM_002318]</td>
<td>-0.396</td>
<td>4.257</td>
<td></td>
</tr>
<tr>
<td>23135</td>
<td>Lysyl oxidase-like 2 (LOXL2), [NM_002318]</td>
<td>-0.329</td>
<td>3.381</td>
<td></td>
</tr>
<tr>
<td>20748</td>
<td>Lysyl oxidase-like 2 (LOXL2), [NM_002318]</td>
<td>-0.306</td>
<td>0.147</td>
<td></td>
</tr>
<tr>
<td>29844</td>
<td>Lysyl oxidase-like 2 (LOXL2), [NM_002318]</td>
<td>-0.287</td>
<td>0.880</td>
<td></td>
</tr>
<tr>
<td>16031</td>
<td>Lysyl oxidase-like 2 (LOXL2), [NM_002318]</td>
<td>-0.264</td>
<td>2.009</td>
<td></td>
</tr>
<tr>
<td>21594</td>
<td>Discoidin domain receptor family, member 2 (DDR2), transcript variant 1, [NM_001014796]</td>
<td>-0.371</td>
<td>1.816</td>
<td></td>
</tr>
<tr>
<td>34185</td>
<td>Tenascin XB (TNXB), transcript variant XB, [NM_019105]</td>
<td>-0.261</td>
<td>2.190</td>
<td></td>
</tr>
</tbody>
</table>

### Ribosomal Activity

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Description</th>
<th>Value1</th>
<th>Value2</th>
</tr>
</thead>
<tbody>
<tr>
<td>42431</td>
<td>Similar to ribosomal protein L28 (LOC402149), [XR_019242]</td>
<td>-0.339</td>
<td>0.381</td>
</tr>
<tr>
<td>37069</td>
<td>Mitochondrial ribosomal protein L39 (MRPL39), transcript variant 1, [NM_017446]</td>
<td>-0.325</td>
<td>1.458</td>
</tr>
<tr>
<td>14029</td>
<td>Mitochondrial ribosomal protein S6 (MRPS6), [NM_032476]</td>
<td>-0.387</td>
<td>1.359</td>
</tr>
<tr>
<td>24937</td>
<td>Ribosomal protein L10 (RPL10), [NM_006013]</td>
<td>-0.321</td>
<td>0.896</td>
</tr>
<tr>
<td>7049</td>
<td>Ribosomal protein L10 (RPL10), [NM_006013]</td>
<td>-0.272</td>
<td>0.500</td>
</tr>
<tr>
<td>10915</td>
<td>Ribosomal protein L18a (RPL18A), [NM_000980]</td>
<td>-0.280</td>
<td>0.660</td>
</tr>
<tr>
<td>9789</td>
<td>Ribosomal protein L18a (RPL18A), [NM_000980]</td>
<td>-0.235</td>
<td>0.647</td>
</tr>
<tr>
<td>21544</td>
<td>Ribosomal protein L28 (RPL28), [NM_000991]</td>
<td>-0.258</td>
<td>1.450</td>
</tr>
<tr>
<td>6338</td>
<td>Ribosomal protein L32 (RPL32), transcript variant 3, [NM_001007074]</td>
<td>-0.208</td>
<td>1.069</td>
</tr>
<tr>
<td>33706</td>
<td>60S ribosomal protein L18a, complete [THC2650296]</td>
<td>-0.245</td>
<td>0.970</td>
</tr>
</tbody>
</table>